833 related articles for article (PubMed ID: 31143953)
21. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
Hosono Y; Nakashima R; Serada S; Murakami K; Imura Y; Yoshifuji H; Ohmura K; Naka T; Mimori T
J Autoimmun; 2017 Feb; 77():116-122. PubMed ID: 27919567
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
23. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
24. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
González-Moreno J; Raya-Cruz M; Losada-Lopez I; Cacheda AP; Oliver C; Colom B
Rheumatol Int; 2018 Jul; 38(7):1293-1296. PubMed ID: 29417209
[TBL] [Abstract][Full Text] [Related]
25. Distribution of anti-melanoma differentiation associated gene 5 (MDA5) IgG subclasses in MDA5+ dermatomyositis.
Chen M; Zhao Q; Diao L; Xue K; Ruan Y; Xue F; Li J; Shi R; Pan M; Zheng J; Cao H
Rheumatology (Oxford); 2021 Dec; 61(1):430-439. PubMed ID: 33742662
[TBL] [Abstract][Full Text] [Related]
26. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
27. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
[TBL] [Abstract][Full Text] [Related]
28. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
29. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody.
Nakashima R; Imura Y; Kobayashi S; Yukawa N; Yoshifuji H; Nojima T; Kawabata D; Ohmura K; Usui T; Fujii T; Okawa K; Mimori T
Rheumatology (Oxford); 2010 Mar; 49(3):433-40. PubMed ID: 20015976
[TBL] [Abstract][Full Text] [Related]
30. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
[TBL] [Abstract][Full Text] [Related]
31. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
Sato S; Kuwana M; Fujita T; Suzuki Y
Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
[TBL] [Abstract][Full Text] [Related]
32. Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study.
Zhou S; Lai J; Wu C; Liu Y; Liu Y; Zhao J; Xu D; Tian X; Li M; Zhao Y; Wang Y; Wang Q; Zeng X
Front Immunol; 2022; 13():928861. PubMed ID: 35983058
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
[TBL] [Abstract][Full Text] [Related]
34. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
[TBL] [Abstract][Full Text] [Related]
35. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
Front Immunol; 2022; 13():845988. PubMed ID: 35320936
[TBL] [Abstract][Full Text] [Related]
36. Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis.
Gan YZ; Zhang LH; Ma L; Sun F; Li YH; An Y; Li ZG; Ye H
Chin Med J (Engl); 2020 Mar; 133(6):644-649. PubMed ID: 32049748
[TBL] [Abstract][Full Text] [Related]
37. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis.
Teruya A; Kawamura K; Ichikado K; Sato S; Yasuda Y; Yoshioka M
Chest; 2013 Dec; 144(6):1934-1936. PubMed ID: 24297126
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
39. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
Ishikawa Y; Kasuya T; Fujiwara M; Kita Y
Medicine (Baltimore); 2020 Sep; 99(37):e21943. PubMed ID: 32925726
[TBL] [Abstract][Full Text] [Related]
40. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
Respir Med; 2011 Sep; 105(9):1380-7. PubMed ID: 21632230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
